安图生物12月23日获融资买入607.35万元，融资余额4.65亿元

Core Viewpoint - Antu Biology's stock experienced a slight decline of 0.42% on December 23, with a trading volume of 39.52 million yuan, indicating a low financing balance relative to its market value and a high short-selling balance compared to historical levels [1]. Financing Summary - On December 23, Antu Biology had a financing buy amount of 6.07 million yuan and a financing repayment of 4.91 million yuan, resulting in a net financing buy of 1.16 million yuan [1]. - The total financing and securities lending balance for Antu Biology reached 470 million yuan, with the financing balance of 465 million yuan accounting for 2.27% of the circulating market value, which is below the 10th percentile level over the past year, indicating a low position [1]. Short Selling Summary - On the same day, Antu Biology repaid 600 shares in short selling and sold 100 shares, with the selling amount calculated at 3,581 yuan based on the closing price [1]. - The short selling balance stood at 460.16 million yuan, with a remaining short selling volume of 128,500 shares, which exceeds the 70th percentile level over the past year, indicating a relatively high position [1]. Company Overview - Antu Biology, established on September 15, 1999, and listed on September 1, 2016, is located in Zhengzhou Economic and Technological Development Zone, specializing in the research, production, and sales of in vitro diagnostic reagents and instruments [1]. - The company's main business revenue composition includes reagents at 86.63%, instruments at 10.99%, other income at 1.40%, and maintenance income at 0.98% [1]. Financial Performance - As of September 30, 2025, Antu Biology reported a total revenue of 3.127 billion yuan, reflecting a year-on-year decrease of 7.48%, and a net profit attributable to shareholders of 860 million yuan, down 10.11% year-on-year [2]. - Since its A-share listing, Antu Biology has distributed a total of 4.046 billion yuan in dividends, with 1.794 billion yuan distributed over the past three years [2]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Antu Biology was 34,000, a decrease of 0.58% from the previous period, with an average of 16,816 circulating shares per person, an increase of 0.58% [2]. - Among the top ten circulating shareholders, Zhonggeng Value Pioneer Stock (012930) ranked third with 7.8361 million shares, a decrease of 1.4173 million shares from the previous period [2].